Evidence map›Paper›PMID 33392802›Full record

Trial reportClinical oral investigations2021

The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Meltem Ozden Yüce, Emine Adalı, Gözde Işık

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical oral investigations, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Interventions for managing medication-related osteonecrosis of the jaw.The Cochrane database of systematic reviews · 2022
    Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Mesenchymal Stem Cells in Socket Healing and MRONJ.Orthodontics & craniofacial research · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Meltem Ozden YüceDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ege University, Izmir, Turkey.
Emine AdalıDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, Izmir Democracy University, Izmir, Turkey. emineadali88@windowslive.com.ORCID http://orcid.org/0000-0002-0623-5746
Gözde IşıkDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ege University, Izmir, Turkey.
Ege University · TRIzmir University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe purpose of this present study was to evaluate the efficiency of the growth factors delivered by concentrated growth factor (CGF) on the healing process of osteoporotic patients with medication-related osteonecrosis of the jaws (MRONJ).

methodsThis randomized controlled study was composed of osteoporotic female patients who were treated with oral bisphosphonates (BPs) and diagnosed with MRONJ. For the CGF group, each patient was treated with a local application of CGF at the surgical site after removing the necrotic bone, while the surgical area was primarily closed as traditional surgical therapy for the control group. The patients underwent clinical examinations for 6 months postoperatively to check the presence of infection and dehiscence.

resultsComplete healing was achieved in 19 patients of 28 patients (mean age: CGF group, 73.57 ± 5.1; control group, 73.64 ± 5.49) diagnosed with MRONJ. There was no significant difference in post-op healing data between groups during healing periods (p > 0.05). In the CGF group (n = 14) in three cases, bone exposure without infection was detected, and one of them showed a recurrent infection. In the control group (n = 14) in six cases, bone exposure without infection was detected, and three of them also showed recurrent infection.

conclusionAlthough our results were not statistically significant, our findings suggest that the local application of CGF appears to be an effective approach to the surgical treatment of MRONJ in osteoporosis patients by improving tissue regeneration. CLINICAL RELEVANCE: A specific treatment protocol to manage MRONJ is still controversial. This study justifies that CGF can be used in combination with surgical treatment.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsOsteoporosisDiphosphonatesFemaleHumansIntercellular Signaling Peptides and ProteinsJawBone Density Conservation AgentsDiphosphonatesIntercellular Signaling Peptides and ProteinsConcentrated growth factorMRONJOsteonecrosisOsteoporosis

Identifiers

PMID33392802
OpenAlexW3119857671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.